Santé

Diseases detection (what makes people sick) ; Delivery of healthcare (treatments & prevention) ; Healthcare financing (who pays for what)

Groupe de Travail - Santé en Europe

Présidente : Raphaela Kitson-Pantano

What? 

A group of 10-15 people from all over Europe, from all realms of the health sector, coming together to discuss challenges linked to health at the European level to foster networks, to draft recommendations for policy at the European level and to enhance better practices and innovative ideas to address the needs of tomorrow on this topic. 

Why? 

“Medicine will move from a reactive to a proactive discipline over the next decade--a discipline that is Predictive, Personalized, Preventive and Participatory (P4). P4 medicine will be fueled by systems approaches to disease, emerging technologies and analytical tools” - such were the words of Hood et al1, in 2011, who thereby coined the term “P4 medicine” 2. Current healthcare practices essentially rely on the emergence of signs and symptoms of human pathologies prior to initiation of interventional modalities. Human genome mapping, the omics revolution and empowering sequencing technologies developed at the turn of the century, have led to new deals and to a switch from population medicine to individual therapies, from curing the disease to preventing it. Predictive and Personalized medicines are the new buzz words that make patients hope for a perfectly adapted treatment to each of our individual illnesses: the right treatment at the right time. Medical genetics, Medical genomics, pharmacogenetics and pharmacogenomics are now an integral part of oncology, psychiatry, pharmacology and almost all fields of medical science and seek to determine the individual profile of the patient and his/her individual response to drugs as a means to follow treatment and prevent relapses. 

Medical progress will mean people will ask more and more for support in navigating through their health journey from anticipating the risks they are exposed to until post-treatment care. They will also trust and choose health players that can help them manage their health efficiently while keeping them healthy (e.g. outcome-based medicine) on top of paying their claims. 

As medicine is evolving from a collective approach to a more individualized approach aiming at keeping people healthy and predicting diseases, the main three elements of the healthcare value chain will be strongly impacted: 

- Diseases detection e.g. what makes people sick: the causes of illness, the diseases themselves and the technologies used to diagnose them will evolve e.g. the generalization of DNA sequencing etc. 

- Delivery of healthcare e.g. how people are treated and the increasing role of prevention: illness treatment will change as medicine will evolve toward a more individualized approach using regenerative medicine… 

- Healthcare financing e.g. who pays for what: Even if state/public funded security systems are still the major payer of healthcare costs, they tend to evolve. As a consequence, new systems are likely to emerge e.g. state disengagement in mature markets vs. universal health coverage in emerging markets etc. 

The EuropaNova Health working group will seek to address the challenges brought about by this evolving health ecosystem and will seek to make recommendations for policy at the European level. 

Augustin Terlinden
Founder of BLUE ANTIDOTE
Nathalie Bufi
Chef Operating Officer of Instent
Pedro Lucas
Chairman and CEO of Cloud Santé

Former leadership of the International Research Laboratories association (LIR). Consultant for the health sector.

Dominique Amory
Partner in Nextep ; CEO of Eli Lilly
Sylvain Bonnet
Président du GT Alimentation ; Président-Fondateur de NL International ; BeautySané

M1 Droit international public, M2 Diplomatie et Négociations stratégiques

Anaïs Darbois-Sage
Chargée de projets à EuropaNova

Age-related biomedical research, Financial markets, Insurance on longevity derivatives, Retirement systems, Health care, Prevention.

Édouard Debonneuil
Co-Director of the International Longevity Alliance Association. Creator of ActuRx
Laura Naessens
Head of Advocacy at Bayer

Private practitioner since 1981. Interest in the role of medical examination, of physical activity for cardiac well-being, cardio-oncology.

Dr. Jean-Pierre Usdin
Cardiologist at the Cabinet d’Esperey. Former Head of the Department of Cardiology (Hôpital Américain de Paris).
Isabelle Zablit
Managing Director WELLFUNDR. Founder & Director of Clavesis.

Prix Jean Perrin, Grand Prix de vulgarisation scientifique

Dr. Dominique Leglu
Editorial director of Sciences et Avenir + La Recherche magazines

Health Innovation Strategist

Pascal Lardier
Health 2.0 Ambassador

Master 1 Études Européennes et Internationales, Master 2 Science politique internationale

Océane Cirera
Project Manager at EuropaNova

Genetics PhD (University of Edinburgh) Masters in European Politics and Administration (College of Europe) Significant experience in Science

Raphaela Kitson-Pantano
Chair of the Alimentation Working Group. Head of International Health Relations at AXA Global Life.

Citoyenne du monde passionnée par les relations exérieures de l'UE, enjeux liés au climat, énergie, culture et participation citoyenne

Lena Morozova-Friha
Déléguée Générale d'EuropaNova

Docteur en droit public. Chargée d’enseignement en droit et institutions européennes, procédures et droit des libertés fondamentales.

Elise Bernard
Directrice des Études d'EuropaNova

Publications associées

Nous n'avons pas de publications associées

Rencontres associées

Nous n'avons pas de rencontres associées